173 related articles for article (PubMed ID: 38180543)
1. A robust optimal control framework for controlling aberrant RTK signaling pathways in esophageal cancer.
Roy S; Pan Z; Abu Qarnayn N; Alajmi M; Alatawi A; Alghamdi A; Alshaoosh I; Asiri Z; Batista B; Chaturvedi S; Dehinsilu O; Edduweh H; El-Adawy R; Hossen E; Mojra B; Rana J
J Math Biol; 2024 Jan; 88(2):14. PubMed ID: 38180543
[TBL] [Abstract][Full Text] [Related]
2. A Fokker-Planck feedback control framework for optimal personalized therapies in colon cancer-induced angiogenesis.
Roy S; Pan Z; Pal S
J Math Biol; 2022 Feb; 84(4):23. PubMed ID: 35212794
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
Kummar S; Gutierrez ME; Chen A; Turkbey IB; Allen D; Horneffer YR; Juwara L; Cao L; Yu Y; Kim YS; Trepel J; Chen H; Choyke P; Melillo G; Murgo AJ; Collins J; Doroshow JH
Eur J Cancer; 2011 May; 47(7):997-1005. PubMed ID: 21247755
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.
Hoffmann S; Burchert A; Wunderlich A; Wang Y; Lingelbach S; Hofbauer LC; Rothmund M; Zielke A
Endocrine; 2007 Apr; 31(2):105-13. PubMed ID: 17873319
[TBL] [Abstract][Full Text] [Related]
5. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines.
Emlet DR; Brown KA; Kociban DL; Pollice AA; Smith CA; Ong BB; Shackney SE
Mol Cancer Ther; 2007 Oct; 6(10):2664-74. PubMed ID: 17938260
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
7. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.
Le XF; Mao W; Lu C; Thornton A; Heymach JV; Sood AK; Bast RC
Cell Cycle; 2008 Dec; 7(23):3747-58. PubMed ID: 19029832
[TBL] [Abstract][Full Text] [Related]
8. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells.
Akagi M; Kawaguchi M; Liu W; McCarty MF; Takeda A; Fan F; Stoeltzing O; Parikh AA; Jung YD; Bucana CD; Mansfield PF; Hicklin DJ; Ellis LM
Br J Cancer; 2003 Mar; 88(5):796-802. PubMed ID: 12618892
[TBL] [Abstract][Full Text] [Related]
9. Advances in targeted therapy for esophageal cancer.
Yang YM; Hong P; Xu WW; He QY; Li B
Signal Transduct Target Ther; 2020 Oct; 5(1):229. PubMed ID: 33028804
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG
Dis Esophagus; 2013 Jul; 26(5):487-95. PubMed ID: 22458639
[TBL] [Abstract][Full Text] [Related]
11. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
[TBL] [Abstract][Full Text] [Related]
12. A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer.
Cao HY; Guo XF; Zhu XF; Li SS; Zhen YS
Oncol Rep; 2017 Jun; 37(6):3329-3340. PubMed ID: 28498434
[TBL] [Abstract][Full Text] [Related]
13. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.
Winder T; Lenz HJ
Gastroenterology; 2010 Jun; 138(6):2163-76. PubMed ID: 20420953
[TBL] [Abstract][Full Text] [Related]
15. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
[TBL] [Abstract][Full Text] [Related]
16. Genetic variants of EGF and VEGF predict prognosis of patients with advanced esophageal squamous cell carcinoma.
Yang PW; Hsieh MS; Huang YC; Hsieh CY; Chiang TH; Lee JM
PLoS One; 2014; 9(6):e100326. PubMed ID: 24945674
[TBL] [Abstract][Full Text] [Related]
17. Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway.
Zhang Q; Yu C; Peng S; Xu H; Wright E; Zhang X; Huo X; Cheng E; Pham TH; Asanuma K; Hatanpaa KJ; Rezai D; Wang DH; Sarode V; Melton S; Genta RM; Spechler SJ; Souza RF
Gastroenterology; 2014 Feb; 146(2):461-72.e6. PubMed ID: 24120473
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
[TBL] [Abstract][Full Text] [Related]
19. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
[No Abstract] [Full Text] [Related]
20. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
